United States-based contract research organisation Vial announced on Sunday that it has named Dr Neeraj Agarwal as scientific advisor for the company's Oncology CRO.
Dr Agarwal is a genitourinary cancer specialist and has been the overall study chair of multiple Phase I, Phase II, and Phase III trials and serves as a steering committee member of numerous other studies. He was named senior director of Clinical Research Innovation at the Huntsman Cancer Institute, University of Utah, where he holds multiple other leadership positions. He is a consultant to the US FDA's Oncology Drug Advisory Committee (ODAC) and heads early therapeutics in the SWOG genitourinary cancers committee.
Dr Agarwal said: "Over the last two decades, the entire process of conducting clinical trials has exponentially grown cumbersome. It is critical for this process to become more efficient to improve administrative work for the investigating teams, make it easier for our patients to enrol, improve the accrual timeline, and expedite and decrease the cost of drug development."
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer